Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucagon-like peptide-1(28-36)amide is a C-terminal nonapeptide metabolite of glucagon-like peptide-1 (GLP-1) generated by the enzymatic cleavage of GLP-1(7-36)amide or GLP-1(9-36)amide by neutral endopeptidase (NEP 24.11 / neprilysin). Unlike intact GLP-1, glucagon-like peptide-1(28-36)amide does not bind to or activate the cell-surface GLP-1 receptor (GLP-1R). Instead, it acts intracellularly as a cell-penetrating peptide, targeting the mitochondria where it binds to mitochondrial trifunctional protein-alpha (MTPα / HADHA). This interaction modulates cellular bioenergetics, shifts substrate utilization to increase glucose oxidation, and inhibits fatty acid oxidation. It also stimulates intracellular cyclic adenosine monophosphate (cAMP) production via soluble adenylyl cyclase (sAC) and activates protein kinase A (PKA), leading to downstream phosphorylation of CREB and beta-catenin. Preclinical studies have demonstrated that glucagon-like peptide-1(28-36)amide exerts cytoprotective, antioxidant, and anti-apoptotic effects in pancreatic beta-cells and hepatocytes, suppresses hepatic gluconeogenesis, improves pyruvate tolerance, and provides cardioprotection against ischemia-reperfusion injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucagon-like peptide-1(28-36)amide.